Source - LSE Regulatory
RNS Number : 1337A
JPMorgan Claverhouse IT PLC
12 August 2024
| JPMORGAN CLAVERHOUSE INVESTMENT TRUST PLC (the 'Company') |
|
| Legal Entity Identifier: 549300NFZYYFSCD52W53 | |
| THE COMPANY ANNOUNCES THE TEN LARGEST INVESTMENTS IN % OF TOTAL ASSETS As at: 31 July 2024 | |
| Shell Plc | 8.6% |
| Astrazeneca Group Plc | 6.4% |
| Hsbc Holdings Plc | 6.0% |
| Bp Plc | 4.1% |
| 3I Group Plc | 3.6% |
| Unilever Plc | 3.5% |
| Gsk Plc | 3.1% |
| Rio Tinto Plc | 3.1% |
| Relx Plc | 2.8% |
| Osb Group Plc | 2.5% |
| Total | 43.7% |
| Excludes Investments in Liquidity stocks | |
| Name of contact and telephone number for queries: | |
| Paul Ainger 0044 207 742 6524 | |
| Name of authorised company official responsible for making this notification: | |
| Anmol Dhillon 020 7742 4000 - Company Secretary | |
| Date: 12 August 2024 |
|
| | |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
